Andres Brainsky

Andres Brainsky has served as Vice President, Clinical Development at Aileron since April 2021. Dr. Brainsky is a physician and pediatric surgeon trained in Bogotá, Colombia, where he practiced Pediatric Surgery for eight years before coming to the US. Dr. Brainsky worked at GlaxoSmithKline for six years where he was a Medical Director for the clinical program of a thrombopoietin receptor agonist developed for several indications, including chronic ITP, hepatitis C induced thrombocytopenia and oncology related thrombocytopenia. Dr. Brainsky joined CSL Behring in January 2013 and worked on the therapeutic areas of Acquired Bleeding, Coagulation and Hematology, acting as TA Head in 2017 and 2018 and becoming an Executive Director in 2019. During Dr. Brainsky’s time at CSL Behring he led the registration trial for prothrombin complex concentrate (PCC) in Japan, a study for fibrinogen concentrate in Congenital Fibrinogen Deficiency and several clinical trials in hemophilia A and B and in von Willebrand’s disease. Between 2018 and 2021 Dr. Brainsky led the Gene Therapy team to a successful initiation of CSL Behring’s first gene therapy clinical trial in Sickle Cell Disease and was the clinical lead in a collaboration with Seattle Children’s Research Institute including gene therapy programs in Wiskott Aldrich Syndrome and X-linked agammaglobulinemia.